ACADIA Pharmaceuticals Inc (ACAD)
15.02
-0.08
(-0.53%)
USD |
NASDAQ |
May 21, 10:42
ACADIA Pharmaceuticals SG&A Expense (Quarterly): 107.99M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 107.99M |
December 31, 2023 | 111.46M |
September 30, 2023 | 97.89M |
June 30, 2023 | 95.97M |
March 31, 2023 | 101.24M |
December 31, 2022 | 104.40M |
September 30, 2022 | 78.11M |
June 30, 2022 | 89.90M |
March 31, 2022 | 96.68M |
December 31, 2021 | 105.91M |
September 30, 2021 | 81.67M |
June 30, 2021 | 96.79M |
March 31, 2021 | 111.66M |
December 31, 2020 | 120.75M |
September 30, 2020 | 81.59M |
June 30, 2020 | 84.34M |
March 31, 2020 | 101.97M |
December 31, 2019 | 91.87M |
September 30, 2019 | 72.70M |
June 30, 2019 | 67.98M |
March 31, 2019 | 93.09M |
December 31, 2018 | 74.27M |
September 30, 2018 | 61.09M |
June 30, 2018 | 69.47M |
March 31, 2018 | 60.93M |
Date | Value |
---|---|
December 31, 2017 | 66.69M |
September 30, 2017 | 61.59M |
June 30, 2017 | 61.12M |
March 31, 2017 | 65.66M |
December 31, 2016 | 57.66M |
September 30, 2016 | 50.53M |
June 30, 2016 | 50.77M |
March 31, 2016 | 27.49M |
December 31, 2015 | 22.62M |
September 30, 2015 | 20.31M |
June 30, 2015 | 21.12M |
March 31, 2015 | 24.26M |
December 31, 2014 | 10.42M |
September 30, 2014 | 8.057M |
June 30, 2014 | 7.952M |
March 31, 2014 | 6.32M |
December 31, 2013 | 4.276M |
September 30, 2013 | 3.797M |
June 30, 2013 | 2.496M |
March 31, 2013 | 2.151M |
December 31, 2012 | 2.298M |
September 30, 2012 | 1.485M |
June 30, 2012 | 1.556M |
March 31, 2012 | 1.66M |
December 31, 2011 | 1.478M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
67.98M
Minimum
Jun 2019
120.75M
Maximum
Dec 2020
95.04M
Average
96.73M
Median
SG&A Expense (Quarterly) Benchmarks
Regulus Therapeutics Inc | 2.786M |
Amylyx Pharmaceuticals Inc | 57.76M |
Alnylam Pharmaceuticals Inc | 210.80M |
Cassava Sciences Inc | 3.701M |
Oragenics Inc | 1.797M |